-
Adicon Launches GuardantOMNI Test to Advance Tumor Therapy Development in China
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory service provider, has announced the launch of its GuardantOMNI test, a 500-gene panel based on blood sample detection, alongside its previously introduced liquid biopsy product, Guardant360. This initiative aims to enhance the development of tumor-targeted drugs and immunotherapies in clinical…
-
Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully completed its initial public offering (IPO) of 33.2 million shares on the Hong Kong Stock Exchange. The shares were priced at HKD 12.32 (USD 1.58) each, with net proceeds expected to reach HKD 83.9 million…
-
Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500
•
China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at the 5th China International Import Expo (CIIE). The collaboration targets the central laboratory program, aiming to enhance clinical studies and drug development plans centered around TruSight Oncology 500 (TSO 500), a research-only pan-cancer detection assay.…
-
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
•
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant’s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant’s liquid biopsy technology, including the Guardant360,…
